Join the Olumiant group to help and get support from people like you.
Olumiant News
AAD: Hair Regrowth Continues to Improve at 76 Weeks With Baricitinib for Severe Alopecia
MONDAY, March 18, 2024 -- Continuous treatment with baricitinib in patients with severe alopecia areata demonstrates improvement in hair regrowth outcomes through 76 weeks of follow-up, according to ...
Risk Profile IDs COVID-19 Patients Who Will Benefit From Baricitinib
MONDAY, Feb. 26, 2024 – The Adaptive COVID-19 Treatment Trial (ACTT) risk profile identifies hospitalized COVID-19 patients who benefit most from baricitinib treatment, according to a study...
Daily Baricitinib Treatment Preserves β-Cell Function in Type 1 Diabetes
THURSDAY, Dec. 7, 2023 – Daily baricitinib treatment over 48 weeks preserves β-cell function in patients with type 1 diabetes diagnosed recently, according to a study published in the Dec. 7 issue ...
Rheumatoid Arthritis Drug, Baricitinib (Olumiant), Could Put Brakes on Type 1 Diabetes
THURSDAY, Dec. 7, 2023 – A drug long used to curb rheumatoid arthritis may be a potent foe against another immune disorder, type 1 diabetes. Australian researchers report that baricitinib (Olumiant)...
Rheumatoid Arthritis Drug, Baricitinib (Olumiant), Could Put Brakes on Type 1 Diabetes
THURSDAY, Dec. 7, 2023 – A drug long used to curb rheumatoid arthritis may be a potent foe against another immune disorder, type 1 diabetes. Australian researchers report that baricitinib (Olumiant)...
Rheumatoid Arthritis Drug, Baricitinib (Olumiant), Could Put Brakes on Type 1 Diabetes
THURSDAY, Dec. 7, 2023 – A drug long used to curb rheumatoid arthritis may be a potent foe against another immune disorder, type 1 diabetes. Australian researchers report that baricitinib (Olumiant)...
Four JAK Inhibitors Have Comparable Efficacy, Safety for RA
FRIDAY, Dec. 1, 2023 – For patients with rheumatoid arthritis, the efficacy and safety of four Janus kinase (JAK) inhibitors is comparable, according to a study published online Nov. 1 in...
A New Treatment Option for a Form of Sudden Hair Loss
THURSDAY, Aug. 17, 2023 – A new type of medication, JAK inhibitors, can effectively treat moderate to severe alopecia areata, a hair loss condition that has been historically hard to treat. A study...
FDA Approves Lilly and Incyte's Olumiant (baricitinib) as First and Only Systemic Medicine for Adults with Severe Alopecia Areata
INDIANAPOLIS, June 13, 2022 /PRNewswire/ – Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ:INCY) announced today that the U.S. Food and Drug Administration (FDA) has approved Olumiant...
FDA Approves Olumiant (baricitinib) Treatment for COVID-19 in Certain Hospitalized Adults
Olumiant is the first and only JAK inhibitor FDA-approved for the treatment of COVID-19 in certain hospitalized adults requiring various degrees of oxygen support INDIANAPOLIS, May 11, 2022...
FDA Medwatch Alert: FDA Requires Warnings About Increased Risk of Serious Heart-Related Events, Cancer, Blood Clots, and Death for JAK Inhibitors That Treat Certain Chronic Inflammatory Conditions
This information is an update to the FDA Drug Safety Communication issued on February 4, 2021. FDA also previously communicated about the safety clinical trial with Xeljanz, Xeljanz XR (tofacitinib)...
FDA Approves Olumiant (baricitinib) 2 mg Tablets for the Treatment of Adults with Moderately-to-Severely Active Rheumatoid Arthritis
INDIANAPOLIS, June 1, 2018 /PRNewswire/ – Eli Lilly and Company (NYSE: LLY) and Incyte Corporation (NASDAQ: INCY) announced today that the U.S. Food and Drug Administration (FDA) has approved the...
Ask a question
To post your own question to this support group, sign in or create an account.
Further information
Related condition support groups
Alopecia, Rheumatoid Arthritis, COVID-19